Company Analysis: AbbVie

Company Analysis: AbbVie

  • November 2017 •
  • 40 pages •
  • Report ID: 5336325 •
  • Format: PDF
Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

Overview – AbbVie looks to offset long-term declines in Humira sales with emerging pipeline portfolio.
Mid-term outlook – Humira will begin to decline in sales from 2019 due to European biosimilar entry in Q4 2018.
Long-term outlook – Pipeline drugs including Venclexta, elagolix, and Rova-T will offset declines in Humira, with the company’s sales set to grow 1.7% by 2026.
Events – FDA approval decision on Mavyret in Q3 2017.

AbbVie has boosted its oncology exposure with a $21bn deal for Pharmacyclics and $5.8bn takeover of Stemcentrx.
AbbVie’s acquisition of Shire was terminated due to US tax regulation changes.
AbbVie seeks to lessen dependency on Humira.
AbbVie will reap rewards from expansion into oncology.
Mavyret approval will take market share from Gilead’s HCV products.

Analysis structure
Company context
How is AbbVie strategically poised out to 2026?
What are AbbVie’s key strengths, weaknesses, opportunities, and threats?
What are AbbVie’s key catalysts over the next four quarters?

Facts and figures
What is AbbVie’s forecasted sales performance out to 2026?
What is the revenue trajectory of AbbVie’s current top 10 products out to 2026?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of AbbVie based on the lifecycle of products?

Key therapy areas
Immunology and inflammation | Oncology | Infectious diseases
Why will specific therapy areas experience the largest growth and decline?
What are the detailed competitive dynamics at play in AbbVie’s important therapeutic markets?
How is AbbVie adapting strategically to internal and external headwinds?